On average, Zepbound (tirzepatide) produces more weight loss than Wegovy (semaglutide). A 2024 head-to-head trial confirmed this, and the separate obesity studies for each drug point the same direction. But “more on average” is a statement about groups, not about you. Tolerability, cost, coverage, and whether you can stay on the drug for years often decide your actual result more than the gap between the two molecules.
What did the direct comparison show?
For a long time the zepbound vs wegovy question rested on separate trials that were never designed to be compared against each other. That changed with a randomized study that put semaglutide and tirzepatide head to head in adults with overweight or obesity. Published in the New England Journal of Medicine in 2024, the results, summarized in the accompanying analysis comparing semaglutide and tirzepatide for weight loss, showed tirzepatide participants losing meaningfully more body weight than semaglutide participants over the study period.
This is the cleanest evidence available, because both groups were treated under the same protocol at the same time. When two drugs are studied separately, differences in enrollment, trial length, and dosing can inflate or hide a real gap. A single trial that randomizes people to one drug or the other removes most of that noise.
What did the standalone obesity trials find?
Before the head-to-head, each drug had its own body of evidence. Tirzepatide was studied in SURMOUNT-1, where adults without diabetes reached average reductions well into the double digits as a percentage of body weight at the higher doses over 72 weeks. A separate trial in Chinese adults, SURMOUNT-CN, reported figures in the same range, which supports that the effect is not limited to one population.
Semaglutide’s obesity program produced strong results too, though the top-line averages generally landed a few points lower than tirzepatide’s. Comparing across those separate programs suggested tirzepatide had the edge, and the direct trial then confirmed it rather than overturning it. That consistency is worth more than any single number.
How big is the difference in practice?
| Point of comparison | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Average weight loss | Higher across trials and the direct comparison | Strong, generally a few points lower |
| Mechanism | Acts on GIP and GLP-1 receptors | Acts on the GLP-1 receptor |
| Track record in obesity | Newer approval | Longer real-world history |
| Weight regain after stopping | Substantial regain reported | Substantial regain reported |
The gap is real, but it is an average. Individual response varies widely. Some people lose more on semaglutide than the typical tirzepatide user does, because biology, side effects, and adherence differ from person to person. Reading the average as a personal guarantee is the mistake that leads to disappointment.
Does the difference hold if you stop?
This is where both drugs behave the same, and it reshapes the whole comparison. In the maintenance trial SURMOUNT-4, people who switched from tirzepatide to placebo regained a large share of what they had lost. The semaglutide maintenance study, STEP 4, told the same story: continued treatment held the loss, and withdrawal reversed it.
So the honest way to read “which loses more weight” is “which loses more weight while you keep taking it.” Neither drug is a short course. A drug you can afford and tolerate for years will beat a slightly stronger drug you quit at month four. That practical truth matters more than a few percentage points on a chart.
Do the benefits go beyond the scale?
Weight is not the only outcome that matters. Tirzepatide was tested in adults with obesity and obstructive sleep apnea, where it reduced the severity of sleep-disordered breathing alongside weight. For someone whose main problem is apnea rather than the number on the scale, that kind of specific benefit can tip a decision more than the raw weight-loss average does.
Semaglutide has its own broad record, including a comparison against an older GLP-1 drug in STEP 8, which showed it outperforming daily liraglutide. The point is that each molecule carries evidence for outcomes beyond weight, and the right choice depends on which of those outcomes you care about.
Where do cost and access fit in?
The stronger drug on paper is useless if you cannot get it or stay on it. Both carry high list prices, and most people pay through insurance, a manufacturer savings program, or a self-pay route. Direct-to-patient services such as Ro, Hims and Hers, Henry Meds, and LillyDirect have made the branded and, in some cases, compounded options easier to reach, and a supervised telehealth practice like FormBlends publishes flat monthly pricing that some cash payers compare against those; for a fuller breakdown of the two drugs side by side you can learn more here.
One caution on the compounded route. Compounded tirzepatide and semaglutide are prepared by compounding pharmacies and are not FDA-approved products. The weight-loss numbers in every trial cited here come from the branded drugs studied under an approved application, so those figures do not automatically transfer to a compounded preparation. The prescribing labels for the branded products, including Zepbound and the diabetes version of the same molecule, Mounjaro, describe the tested doses and known risks.
Key takeaways
- Tirzepatide (Zepbound) produced more average weight loss than semaglutide (Wegovy), confirmed in a 2024 head-to-head trial.
- The gap is an average, and individual results vary widely on both drugs.
- Both drugs lose their effect after stopping, so long-term adherence decides the real outcome.
- Compounded versions are not FDA-approved and were not the products studied in the trials.
See also: Best Accident Lawyers in Arizona: A Practical Guide to Choosing the Right Legal Help
Frequently asked questions
Which drug produced more weight loss in a direct comparison?
In the SURMOUNT-5 head-to-head trial published in 2024, adults taking tirzepatide (Zepbound) lost more weight on average than those taking semaglutide (Wegovy). The average difference was several percentage points of body weight over the study period.
Does more weight loss on average mean it will work better for me?
Not necessarily. Trial averages describe groups, not individuals. Some people lose a great deal on either drug, and some respond poorly to both. Tolerability, side effects, and whether you can stay on the medication often decide the outcome more than the average gap.
Do the results hold if I stop taking the medication?
No. Maintenance trials for both molecules showed that stopping treatment led to substantial weight regain. These drugs manage weight while taken rather than curing the condition, so the comparison assumes continued use.
Is compounded tirzepatide or semaglutide the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule, but they were not studied in the trials that generated the published weight-loss figures.
Are there reasons to choose Wegovy despite the smaller average loss?
Yes. Coverage, cost, tolerability, and a longer track record can all favor semaglutide for a given person. The molecule with the larger average result is not automatically the right choice for every case.
